Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
04-05-01 Anti-obesity drugs acting on the gastro-intestinal tract
| Liraglutide Saxenda® |
|
Formulary
|
6mg/ml solution for injection 3ml pre-filled pens liraglutide is recommended as an option in overweight and obesity as long as it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service
|
 MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued NICE TA664: Liraglutide for managing overweight and obesity |
|
for NICE TA749 Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)
| Semaglutide Wegovy® |
|
Formulary
|
Solution for injection in pre filled pen 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg
Only available via referral to a Tier 3 Weight Management Service (though not commercially available yet)
|
|
NICE TA875: Semaglutide for managing overweight and obesity |
|
|
Links
- MHRA Drug Safety Update Aug 2019: Naltrexone/bupropion (Mysimba): risk of adverse reactions that could affect ability to drive
- MHRA Drug Safety Update Jue 2019: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
- MHRA: GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued
MHRA: Interaction with HIV medicines- NICE CG189: Obesity: identification, assessment and management
- NICE TA664: Liraglutide for managing overweight and obesity
- NICE TA664: Liraglutide for managing overweight and obesity
- NICE TA749: Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal)
- NICE TA875 Semaglutide for managing overweight and obesity
- NICE TA875: Semaglutide for managing overweight and obesity
- NICETA910:Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal)